Skip to main content
x

Recent articles

Nerviano becomes a targeted PARP player

Two cast-offs comprise the private group's attempts to hit PARP1 and PARP7.

Roche doubles down on Poseida

A $1bn buyout gives Roche more allogeneic Car-T projects, plus non-viral gene therapy contenders.

Truqap could fill a prostate cancer gap

The AKT inhibitor prevails in hormone-sensitive disease, but other studies have been delayed.

Targeted lung cancer niche sees a German pharma battle

But could toxicity be holding back filing plans?

Kyowa buys into menin, but it's not Syndax's

Syndax scored the first menin approval, but Kura is first with a licensing deal.

Genmab formalises the challenge against its partner

GEN1286/PRO1286 features among the latest industry projects to enter clinical trials.

Most Popular